Tag: date

In Partnership with the California New Car Dealers Association (CNCDA), DCG to Host Private Gathering for Industry Leaders During Monterey Car Week

GUELPH, Ontario, July 10, 2025 (GLOBE NEWSWIRE) -- Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) today announced that it will release its financial results for the Second Quarter ended June 28, 2025, on Thursday, July 24, 2025, after markets close. Following the release of its financial results, HPS will hold a conference call and webcast on Friday, July 25, 2025, at 9:00 a.m. Eastern Time.

Not for distribution to United States newswire services or for dissemination in the United States

Company Achieves Breakout Quarter as Turnaround Strategy Gains Traction; Clean-Tech Product Launches Poised to Accelerate Growth

New York, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Chief Executive Officer James Walker will participate in a fireside chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear Virtual Conference hosted by Sameer Joshi, Senior Cleantech Analyst at H.C. Wainwright, on July 15, 2025 at 9:00 a.m., Eastern time.

BOCA RATON, FL, July 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 153,225 Solana (“SOL”) at an average purchase price of $154.85 and valued at approximately $23.72 million. Following this transaction, DeFi Dev Corp. now holds approximately 846,630 SOL and SOL equivalents, including staking rewards, making the Company the largest Solana treasury company, by both total holdings and market capitalization.

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.